Unknown

Dataset Information

0

Effects of ASKP1240 combined with tacrolimus or mycophenolate mofetil on renal allograft survival in Cynomolgus monkeys.


ABSTRACT:

Background

Blocking the CD40-CD154 signal pathway has previously shown promise as a strategy to prevent allograft rejection. In this study, the efficacy of a novel fully human anti-CD40 monoclonal antibody-ASKP1240, administered as a monotherapy or combination therapy (subtherapeutic dose of tacrolimus or mycophenolate mofetil), on the prevention of renal allograft rejection was evaluated in Cynomolgus monkeys.

Methods

Heterotopic kidney transplants were performed in ABO-compatible, stimulation index 2.5 or higher in the two-way mixed lymphocyte reaction monkey pairs. Animals were divided into 12 groups and observed for a maximum of 180 days. Histopathologic, hematology, and biochemistry analyses were conducted in all groups. Cytokine release (interleukin [IL]-2, IL-4, IL-5, IL-6, tumor necrosis factor, and interferon-γ) was investigated in several groups.

Results

ASKP1240 prolonged renal allograft survival in a dose-dependent manner in monotherapy. Low-dose (2 mg/kg) or high-dose (5 mg/kg) ASKP1240, in combination with mycophenolate mofetil (15 mg/kg) or tacrolimus (1 mg/kg), showed a significantly longer allograft survival time compared with monotherapy groups. No obvious side effects including drug-related thromboembolic complications were found. Cytokine release was not induced by ASKP1240 administration.

Conclusion

The present study indicates that ASKP1240, alone or in combination with other immunosuppressive drugs, could be a promising antirejection agent in organ transplantation.

SUBMITTER: Song L 

PROVIDER: S-EPMC4175122 | biostudies-literature | 2014 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Effects of ASKP1240 combined with tacrolimus or mycophenolate mofetil on renal allograft survival in Cynomolgus monkeys.

Song Lijun L   Ma Anlun A   Dun Hao H   Hu Yanxin Y   Zeng Lin L   Bai Jieying J   Zhang Guangzhou G   Kinugasa Fumitaka F   Sudo Yuji Y   Miyao Yasuhiro Y   Okimura Kazumichi K   Miura Toru T   Daloze Pierre P   Chen Huifang H  

Transplantation 20140801 3


<h4>Background</h4>Blocking the CD40-CD154 signal pathway has previously shown promise as a strategy to prevent allograft rejection. In this study, the efficacy of a novel fully human anti-CD40 monoclonal antibody-ASKP1240, administered as a monotherapy or combination therapy (subtherapeutic dose of tacrolimus or mycophenolate mofetil), on the prevention of renal allograft rejection was evaluated in Cynomolgus monkeys.<h4>Methods</h4>Heterotopic kidney transplants were performed in ABO-compatibl  ...[more]

Similar Datasets

| S-EPMC11654433 | biostudies-literature
| S-EPMC5786104 | biostudies-literature
| S-EPMC9145025 | biostudies-literature
| S-EPMC2826576 | biostudies-literature
| S-EPMC10530433 | biostudies-literature
| S-EPMC5593662 | biostudies-literature
2017-01-01 | GSE76885 | GEO
| S-EPMC4254196 | biostudies-literature
| S-EPMC4422949 | biostudies-literature